Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023. In the quarter to September 2025, revenue grew 392.0%, EPS grew 445.2% and free cash flow grew 114.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow CARM
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
25.34 | 14.68 | 50.42 | 48.12 | 55.39 | 162.64 | 52.00 | 77.61 | 17.91 |
Receivables |
— | — | — | — | — | 24.49 | — | — | — |
Total current assets |
25.93 | 14.98 | 51.76 | 54.45 | 62.87 | 205.61 | 54.59 | 80.47 | 23.83 |
Property, Plant, Equpment (Net) |
0.80 | 0.52 | 0.32 | 0.24 | 0.12 | 0.04 | 8.63 | 6.76 | 4.39 |
Goodwill and Intangible Assets (Total) |
77.36 | 59.46 | 59.46 | 59.46 | 59.46 | 27.76 | — | — | — |
Long-term assets (Other) |
0.01 | 0.13 | 0.02 | 0.22 | 0.37 | 7.34 | — | — | — |
Total non-current assets |
78.17 | 60.12 | 59.81 | 59.92 | 59.96 | 35.14 | 17.56 | 9.08 | 6.63 |
Total Assets |
104.10 | 75.10 | 111.56 | 114.37 | 122.82 | 240.75 | 72.15 | 89.55 | 30.46 |
Accounts Payable |
1.67 | 0.91 | 1.37 | 1.90 | 3.10 | 2.85 | 1.73 | 3.93 | 2.08 |
Accrued Expenses |
1.77 | 3.81 | 4.75 | 6.17 | 3.97 | 8.26 | 10.36 | 7.66 | 7.45 |
Current Part of Capital Lease |
— | — | — | — | — | — | 1.16 | 0.54 | 0.91 |
Current Revenue (Deferred) |
0.43 | — | — | — | 1.50 | — | 2.46 | 1.41 | 3.73 |
Other current liabilities |
0.11 | 3.81 | 4.75 | 0.45 | 9.47 | 0.46 | 0.52 | 0.97 | 1.06 |
Total current liabilities |
3.98 | 4.72 | 6.11 | 8.52 | 18.05 | 11.57 | 19.67 | 15.91 | 16.06 |
Long Term Debt (Total) |
— | — | — | — | — | — | 34.59 | 0.33 | 0.02 |
Non-current Revenue (Deferred) |
— | — | — | — | 1.50 | 1.50 | 45.00 | 45.00 | 41.25 |
Long Term Tax Liability (Deferred) |
16.34 | 12.53 | 12.53 | 12.53 | 12.53 | 3.97 | — | — | — |
Liabilities (Preferred Stock) |
— | — | — | — | — | — | 107.81 | 0.00 | — |
Non-current Liabilities (Other) |
45.11 | 39.82 | 48.71 | 120.02 | 99.97 | 52.00 | 6.78 | 0.93 | 0.32 |
Total non-current liabilities |
61.44 | 52.34 | 61.24 | 132.55 | 114.00 | 57.47 | 195.15 | 47.11 | 42.31 |
Total liabilities |
65.42 | 57.06 | 67.35 | 141.07 | 132.05 | 69.04 | 214.82 | 63.02 | 58.37 |
Additional Paid In Capital |
161.96 | 170.33 | 230.15 | 266.72 | 306.55 | 487.77 | 1.20 | 271.59 | 277.63 |
Common Stock (Net) |
0.03 | 0.04 | 0.08 | 0.11 | 0.14 | 0.20 | 0.00 | 0.04 | 0.04 |
Retained Earnings |
(123.31) | (152.33) | (186.02) | (293.52) | (315.92) | (316.26) | (158.22) | (245.10) | (305.58) |
Common Equity (Total) |
38.68 | 18.03 | 44.21 | (26.70) | (9.23) | 171.71 | (142.67) | 26.53 | (27.91) |
Shareholders Equity (Total) |
38.68 | 18.03 | 44.21 | (26.70) | (9.23) | 171.71 | (142.67) | 26.53 | (27.91) |
Shareholders Equity and Liabilities (Total) |
104.10 | 75.10 | 111.56 | 114.37 | 122.82 | 240.75 | 72.15 | 89.55 | 30.46 |
Shares (Common) |
1.23 | 1.74 | 3.87 | 5.34 | 7.02 | 9.97 | 2.22 | 40.61 | 41.75 |
Shareholders Equity (Tangible) |
(38.69) | (41.43) | (15.26) | (86.16) | (68.69) | 143.95 | (142.67) | 26.53 | (27.91) |
Net Debt |
(25.34) | (14.68) | (50.42) | (48.12) | (55.39) | (162.64) | (17.41) | (77.28) | (17.89) |
Total Debt |
— | — | — | — | — | — | 34.59 | 0.33 | 0.02 |